AZD3152 for preventing COVID-19

AZD3152 is currently in clinical development for the prevention of COVID-19. COVID-19 is an infectious respiratory disease caused by the severe acute respiratory syndrome-coronavirus 2, SARS-CoV-2. The main symptoms of COVID-19 infection are fever, a new continuous cough, and loss of taste or smell. In some patients, COVID-19 may result in severe complications such as acute respiratory distress syndrome, blood clotting, acute heart or kidney injury and sepsis. Hospitalisation and death rates amongst COVID-19 patients remains high. Patients with conditions that cause immune impairment, who are less likely to mount an adequate protective response after COVID-19 vaccination, are at high risk of developing severe COVID-19 if they were to become infected. There is a need to develop additional therapeutics to protect these vulnerable patients and reduce the risk of poor outcomes from exposure to COVID-19.